Abstract:Fragile X syndrome (FXS) is the most common genetic cause of intellectual disability and the most common single-gene cause of autism. It is caused by mutations on the fragile X mental retardation gene (FMR1) and lack of fragile X mental retardation protein, which in turn, leads to decreased inhibition of translation of many synaptic proteins. The metabotropic glutamate receptor (mGluR) hypothesis states that the neurological deficits in individuals with FXS are due mainly to downstream consequences of overstimulation of the mGluR pathway. The main efforts have focused on mGluR5 targeted treatments; however, investigation on the gamma-aminobutyric acid (GABA) system and its potential as a targeted treatment is less emphasized. The fragile X mouse models (Fmr1-knock out) show decreased GABA subunit receptors, decreased synthesis of GABA, increased catabolism of GABA, and overall decreased GABAergic input in many regions of the brain. Consequences of the reduced GABAergic input in FXS include oversensitivity to sensory stimuli, seizures, and anxiety. Deficits in the GABA receptors in different regions of the brain are associated with behavioral and attentional processing deficits linked to anxiety and autistic behaviors. The understanding of the neurobiology of FXS has led to the development of targeted treatments for the core behavioral features of FXS, which include social deficits, inattention, and anxiety. These symptoms are also observed in individuals with autism and other neurodevelopmental disorders, therefore the targeted treatments for FXS are leading the way in the treatment of other neurodevelopmental syndromes and autism. The GABAergic system in FXS represents a target for new treatments. Herein, we discuss the animal and human trials of GABAergic treatment in FXS. Arbaclofen and ganaxolone have been used in individuals with FXS. Other potential GABAergic treatments, such as riluzole, gaboxadol, tiagabine, and vigabatrin, will be also discussed. Further studies are needed to determine the safety and efficacy of GABAergic treatments for FXS.

Pharmacological management of fragile X syndrome: a systematic review and narrative summary of the current evidence

Potential Pharmacological Treatment of Fragile X Syndrome During Adulthood

New Targeted Treatments for Fragile X Syndrome

Fragile X Syndrome: From Molecular Aspect to Clinical Treatment

Proteomics insights into fragile X syndrome: Unraveling molecular mechanisms and therapeutic avenues

Developmental studies in fragile X syndrome

Epigenetic insights into Fragile X Syndrome

Fragile X Targeted Pharmacotherapy: Lessons Learned and Future Directions

State‐of‐the‐art therapies for fragile X syndrome

Targeted Treatments for Fragile X Syndrome

Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders

Modelling fragile X syndrome in the laboratory setting: A behavioral perspective

Modulation of the GABAergic pathway for the treatment of fragile X syndrome

New perspectives on the biology of fragile X syndrome.

Modeling Fragile X Syndrome: Characterizing Fmr1 Gene Knockout Mice across Genotype, Behavior, and Morphology

Fragile X Syndrome: A Review for General Pediatricians

Mechanisms of Genome Instability in the Fragile X-Related Disorders

Identification of Fragile X Syndrome Specific Molecular Markers in Human Fibroblasts: A Useful Model to Test the Efficacy of Therapeutic Drugs

Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes

Fragile X and autism: Intertwined at the molecular level leading to targeted treatments

From wings to whiskers to stem cells: why every model matters in fragile X syndrome research